Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
about
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesSkeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney DiseaseOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventionsOnly minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite - 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney DiseaseReduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease.Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.Raloxifene improves skeletal properties in an animal model of cystic chronic kidney diseaseSclerostin is essential for alveolar bone loss in occlusal hypofunctionInhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.Role and mechanism of action of sclerostin in bone.The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease.The Expanding Life and Functions of Osteogenic Cells: From Simple Bone-Making Cells to Multifunctional Cells and Beyond.Application of anti-Sclerostin therapy in non-osteoporosis disease models.Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy.
P2860
Q26744599-67C693F3-AC86-4D3C-9D38-E2FAC95F40BCQ27334345-76B98403-D9A8-48F7-9097-A860549B9A29Q30235173-2D0D0783-3AE5-406A-81A3-F37F8824D5D0Q35661168-2DFB18D6-E0A6-45F6-9BB5-BFFA538BA2CEQ36104700-06C9C74C-327F-4139-97D5-715D0C349A21Q36155291-4CF183B0-1542-4D50-B5E7-212A29344DB2Q36497898-B25CF1CD-0265-4920-9D3E-CAF34FDB1D15Q36666085-9532721F-46DB-4CF3-B161-B6462EF3C7C2Q36823369-9B161699-F383-47FF-A1A6-EA6AF6132832Q36824778-B74C4518-D501-4D54-AFAF-6F3734AB29EAQ37418997-B16CEB91-3055-45B8-AD40-5437B2675D7FQ38569480-7009CB9D-C95F-48F1-82CB-0C2C85B869DBQ38807230-587DEE93-1A90-41CF-AA99-08134B4D382BQ38810794-63EC691B-0954-46F0-BC38-CA3790F12B4EQ39101623-2A1DC4D7-471E-41A3-89D4-9FF5B60E7814Q39239811-A67FE65C-6D4E-4E12-B3C5-283F84F52E8BQ39255870-5531FD4C-F2DC-47DE-9769-7542964BD36FQ41146384-F29B4426-5B2C-4354-A625-2910DEDDEB2EQ49719211-02CF262B-5EEE-493D-B67A-EB289A024851Q50069952-04AD987A-E56B-49D7-A3D1-471CB4C4F079Q51363424-0B3A3769-45BC-4C47-81C6-316039946A38Q55026099-9511CF5B-85E9-4ED8-A1B1-1F91EA7E3B55
P2860
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@ast
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@en
type
label
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@ast
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@en
prefLabel
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@ast
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@en
P2093
P2860
P356
P1476
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
@en
P2093
Christopher L Newman
Ina Kramer
Matthew R Allen
Michaela Kneissel
Neal X Chen
Sharon M Moe
Vincent H Gattone
P2860
P304
P356
10.1002/JBMR.2372
P577
2015-03-01T00:00:00Z